Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/CHMP/297822/2011 (15.4.11) |
Publication Date | 15/04/2011 |
Content Type | News |
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in April 2011, recommended that the product information for Pandemrix should be amended to advise prescribers to take into account preliminary results from epidemiological studies on Pandemrix and narcolepsy, and to perform an individual benefit-risk assessment when considering the use of Pandemrix in children and adolescents. This is an interim measure pending the outcome of the European review, expected to conclude in July 2011. |
|
Source Link | http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001244.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |